New drug shows promise against rare liver infection
NCT ID NCT06505928
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests a new drug called hepalatide (L47) in 90 adults with chronic hepatitis D, a serious liver infection. Participants receive either a low or high dose of hepalatide daily for 48 weeks, or delayed treatment. The main goal is to see if the drug can lower the virus level and improve liver health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hepalatide (L47), a drug given as a daily injection
What this could lead to
If it works, this could point toward a new treatment option for chronic hepatitis D, a serious liver disease with few approved therapies.
What could go wrong
This is an early Phase 2 trial with only 90 participants, so results may not apply to everyone. The drug may not show enough benefit or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS D are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Center for Communicable Diseases
Ulaanbaatar, Mongolia
-
National cancer canter of Monglia
Ulaanbaatar, 13370, Mongolia